News

Malignant glioma is expected to be treated by NK cell therapy

Malignant glioma is expected to be treated by NK cell therapy. Recently, the FDA granted the NK cell therapy CYNK-001 “orphan drug”, which is derived from human placental hematopoietic stem cells, for the treatment of patients with malignant glioma.

CYNK-001 is a non-genetically modified, cryopreserved, natural killer (NK) cell therapy derived from human placental hematopoietic stem cells.

▌”The King of Brain Cancer”——Glioma

Brain tumors are roughly divided into three categories: benign, low-grade and malignant. In China, its morbidity and mortality rank first in the world.

Among them, most benign brain tumors (meningiomas, pituitary tumors, etc.) can be cured by surgery; 70% of low-grade brain tumors (precancerous lesions, low-malignant gliomas) can become cancerous.

Glioma is a common malignant brain tumor, accounting for about 50%. Because of the rapid progress of the disease, short course of disease, and extremely poor prognosis, it is also known as the “king of brain cancer”.

The treatment of brain tumors is more difficult, because the brain is the human body’s “headquarters” and is in charge of various important physiological functions of the human body. A little careless treatment can affect the normal function of the human body, and even cause death and disability.

Dr. Keith Black, MD, a cooperative expert of the Good Doctor Medical Network, a well-known American neurosurgery expert, and chief physician of the Institute of Neurosurgery and Brain Tumor Center of Cedar-Sinai Medical Center, said:

Brain tumor surgery is difficult to cut clean, and it is easy to recur. In addition, there is a layer in the brain called the blood-brain barrier (BBB), which prevents most small molecule drugs and large molecule drugs from entering the brain tissue, limiting the application of drugs.

However, in recent years, various medical technologies have developed rapidly, and it is expected that anti-tumor therapy can be carried out through the blood-brain barrier to improve the prognosis.

▌NK therapy derived from placenta: CYNK-001

CYNK-001 is derived from placental hematopoietic stem cells and is a non-genetically modified natural killer (NK) cell therapy that can be widely used in various organs and tissues.

In clinical trials, CYNK-001 has confirmed a series of biological activities of NK cells.

Currently, the drug is being studied for the treatment of acute myeloid leukemia (AML), multiple myeloma (MM), and as a potential therapy for various solid tumors.

In addition, clinical research on CYNK-001 for the treatment of new coronavirus infections is also underway. Because NK cells are an important part of the natural immune system, they participate in the immune response to a variety of viruses and can effectively protect the body from viral infections.

Previously, the drug had been approved by the FDA as a fast track for the treatment of adult patients with glioblastoma multiforme (GBM).

In a phase 1 clinical trial, the drug’s efficacy in patients with recurrence of glioblastoma multiforme (GBM) is being studied, 36 patients are planned to be recruited, and the expected completion date is February 2024.

CYNK-001 has great potential in the treatment of malignant glioma. It is hoped that the drug can complete the trial as soon as possible and benefit more patients with brain tumors.

▌What are the new therapies for brain tumors?

At present, the treatment methods for brain tumors mainly include: surgery, radiotherapy, chemotherapy/targeted therapy, immunotherapy, targeted tumor stem cell therapy, etc. The application of advanced imaging technologies such as near-infrared broad-spectrum imaging (NIR) systems, nanotechnology, etc. It is also very important.

Dr Black and his team have developed a new type of nanomedical imaging agents and drugs that can pass through the blood-brain barrier/blood tumor barrier (BBB/BTB), which can accurately target cancer cells, improve the accuracy of MRI diagnosis, and release nano Drug treatment of primary or metastatic brain tumors.

Since 1987, Dr Black has been committed to the treatment and research of brain tumors for more than 30 years and completed more than 6,000 brain tumor operations. Dr Black is a top brain tumor expert in the United States and even the world. The brain tumor vaccine he and his team are studying has become one of the largest clinical trial sites for brain tumor vaccines in the United States.

For the treatment of difficult and serious diseases such as malignant brain tumors, choice is more important than effort. First of all, the treatment direction must be clarified. Today, through the International Teleconsultation Platform for Good Doctors, domestic patients can have timely consultations with tens of thousands of authoritative American experts, including Dr Black, to make the best treatment plan together with the help of foreign experts.

(source:internet, reference only)

Disclaimer of medicaltrend.org